THE USE OF BISPHOSPHONATE FOR THE PALLIATIVE TREATMENT OF PAINFUL BONE METASTASIS DUE TO HORMONE REFRACTORY PROSTATE CANCER
Author:
Affiliation:
1. From the Departments of Urology, Philipps-University, Marburg and University of Cologne, Cologne, Germany
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Urology
Reference25 articles.
1. Cancer statistics 1997;Parker;CA Cancer J Clin,,1997
2. The biology of hormone refractory prostate cancer. Why does it develop?;Issacs;Urol Clin North Am,1999
3. Complications of advanced prostate cancer;Smith;Urology,1999
4. Morphometric evidence for bone resorption and replacement in prostate cancer;Clarke;Brit J Urol,1991
5. Current use of bisphophonates in oncology. International Bone and Cancer Study Group;Body;J Clin Oncol,,1998
Cited by 106 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Targeted Radionuclide Therapy for Bone Metastasis;Nuclear Oncology;2022
2. Targeted Radionuclide Therapy for Bone Metastasis;Nuclear Oncology;2022
3. Side effects of incardronate disodium compared to pamidronate disodium in the treatment of bone metastasis pain: a systematic review and meta-analysis;Annals of Palliative Medicine;2021-11
4. Bisphosphonates or RANK-ligand-inhibitors for men with prostate cancer and bone metastases: a network meta-analysis;Cochrane Database of Systematic Reviews;2020-12-03
5. Treatment of chronic cancer pain in urologic patients;Serbian Journal of Anesthesia and Intensive Therapy;2019
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3